In patients with NAFLD, lipotoxic hepatocytes release exosomes highly expressing MLK3, and multiple miRNAs in serum of patients, such as miR-34a, miR-122, and miR-192, could be used as biomarkers of NAFLD [70] (Table 1). The gene discussed is MAP3K11; the disease is metabolic dysfunction-associated steatotic liver disease.